Osteoarthritis of the knee and hip. Part I: Aetiology and pathogenesis as a basis for pharmacotherapy

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 5, 2012, Pages 617-625

  Adatia, Aleem ^a   Rainsford, K D ^b   Kean, Walter F ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

bone; cartilage; ibuprofen; inflammation; osteoarthritis

Indexed keywords

ANALGESIC AGENT; IBUPROFEN; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA;

BONE EROSION; BONE REMODELING; CALCIFICATION; CARDIOVASCULAR DISEASE; CARTILAGE CELL; CARTILAGE DEGENERATION; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HIP OSTEOARTHRITIS; HUMAN; HYALINE CARTILAGE; HYPERTENSION; JOINT DEGENERATION; KIDNEY DISEASE; KIDNEY FUNCTION; KNEE OSTEOARTHRITIS; LIVER DISEASE; LIVER TOXICITY; MOLECULAR PATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NERVE FIBER; NERVE FIBER A DELTA; NERVE FIBER C; NOCICEPTION; OSTEOPHYTE; PAIN THRESHOLD; PATHOGENESIS; PERIOSTEUM; PREVALENCE; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVIUM;

ARTHRALGIA; CARTILAGE, ARTICULAR; HIP; HIP JOINT; HUMANS; INFLAMMATION MEDIATORS; KNEE; KNEE JOINT; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE;

EID: 84859591727     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01458.x     Document Type: Review

References (71)

1. Dieppe PA, Lohmander LS,. Pathogenesis and management of pain in osteoarthritis. Lancet 2005; 365: 965-973.
2. Buchanan WW, Kean WF,. Osteoarthritis I: epidemiological risk factors and historical considerations. Inflammopharmacology 2002; 10: 5-21.
3. Buchanan WW, et al,. History and current status of osteoarthritis in the population. Inflammopharmacology 2003; 11: 301-316.
4. Altman RD,. Classification of disease: osteoarthritis. Semin Arthritis Rheum 1991; 20 (S2): 40-47.
5. Buchanan WW, Kean WF,. Osteoarthritis II: pathology and pathogenesis. Inflammopharmacology 2002; 10: 23-52.
6. Buchanan WW, Kean WF,. Osteoarthritis IV: clinical therapeutic trials and treatment. Inflammopharmacology 2002; 10: 75-149.
7. Michael JW, et al,. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. Dtsch Arztebl Int 2010; 107: 152-162. [Erratum ibid, p. 292].
8. Hungin APS, Kean WF,. Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis? Am J Med 2001; 110: 8S-11S.
9. Roberts J, Burch TJ,. Prevalence of osteoarthritis in adults by age, sex, race and geographic area, United States 1960-1962. National Center for Health Statistics: Vital and Health Statistics: Data from the National Health Survey. Washington DC, US Government Printing Office, US Public Health Service Publication, 1000, Series 11, No. 15, 1966.
10. Zhang Y, Jordan JM,. Epidemiology of osteoarthritis. Rheum Dis Clin North Am 2008; 34: 515-529.
11. Lawrence RC, et al,.; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26-35.
12. Mendel OI, et al,. Osteoarthritis and vascular diseases in elderly patients: clinical and pathogenic interrelationships. Adv Gerontol 2010; 23: 304-313.
13. Forestier R, et al,. Prevalence of generalized osteoarthritis in a population with knee osteoarthritis. Joint Bone Spine 2011; 78: 275-278.
14. Nüesch E, et al,. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011; 342: d1165.
15. Fransen M, et al,. The epidemiology of osteoarthritis in Asia. Int J Rheum Dis 2011; 14: 113-121.
16. Kopec JA, et al,. Development of a population-based microsimulation model of osteoarthritis in Canada. Osteoarthritis Cartilage 2010; 18: 303-311.
17. Hunter DJ, et al,. The symptoms of osteoarthritis and the genesis of pain. Med Clin North Am 2009; 93: 83-100.
18. Buckwalter JA, Martin JA,. Osteoarthritis. Adv Drug Deliv Rev 2006; 58: 150-167.
19. Losina E, et al,. Impact of obesity and knee osteoarthritis on morbidity in older Americans. Ann Intern Med 2011; 154: 217-226.
20. Denisov LN, et al,. Role of obesity in the development of osteoarthritis and concomitant diseases. Ter Arkh 2010; 82: 34-37.
21. Ray L, et al,. Mechanisms of association between obesity and chronic pain in the elderly. Pain 2011; 152: 53-59.
22. Lawrence JS, et al,. Osteoarthritis prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 1966; 25: 1-24.
23. Duncan R, et al,. Symptoms and radiographic osteoarthritis: not as discordinant as they are made out to be? Ann Rheum Dis 2007; 66: 86-91.
24. Cooper C, et al,. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum 2000; 43: 995-1000.
25. Cibere J, et al,. Association of clinical findings with pre-radiographic and radiographic knee osteoarthritis in a population-based study. Arthritis Care Res 2010; 62: 1691-1698.
26. Gibson K, et al,. Measurement of varus/valgus alignment in obese individuals with knee osteoarthritis. Arthritis Care Res 2010; 62: 690-696.
27. Holt HL, et al,. Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60-64 year-old US adults. Osteoarthritis Cartilage 2011; 19: 44-50.
28. Amin S, et al,. Cigarette smoking and the risk for cartilage loss and knee pain in men with knee osteoarthritis. Ann Rheum Dis 2007; 66: 18-22.
29. Kellgren JH, Lawrence JS,. Osteo-arthritis and disk degeneration in an urban population. Ann Rheum Dis 1958; 17: 388-397.
30. Kerkhof HJ, et al,. A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum 2010; 62: 499-510.
31. Valdes AM, Spector TD,. Genetic epidemiology of hip and knee osteoarthritis. Nat Rev Rheumatol 2011; 7: 23-32.
32. Kean WF, et al,. Women with pain due to osteoarthritis: the efficacy and safety of a once-daily formulation of tramadol. Pain Med 2009; 10: 1001-1011.
33. Snelling S, et al,. Genetic association analysis of LRCH1 as an osteoarthritis susceptibility locus. Rheumatol 2007; 46: 250-252.
34. Evangelou E, et al,. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum 2009; 60: 1710-1721.
35. Waarsing JH, et al,. Osteoarthritis susceptibility genes influence the association between hip morphology and osteoarthritis. Arthritis Rheum 2011; 63: 1349-1354.
36. Takahashi H, et al,. Prediction model for knee osteoarthritis based on genetic and clinical information. Arthritis Res Ther 2010; 12: R187.
37. Kerkhof HJ, et al,. Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage 2011; 19: 254-264.
38. Valdes AM, et al,. Genome-wide association scan identifies a prostaglandin-endoperoxide synthase-2 variant involved in risk of knee osteoarthritis. Am J Hum Genet 2008; 82: 1231-1240.
39. Kerkhof HJ, et al,. Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthritis Cartilage 2011; 19: 265-271.
40. Chen HC, et al,. Genome-wide linkage analysis of quantitative biomarker traits of osteoarthritis in a large, multigenerational extended family. Arthritis Rheum 2010; 62: 781-790.
41. Duan C, et al,. Comparative analysis of gene expression profiles between primary knee osteoarthritis and an osteoarthritis endemic to Northwestern China, Kashin-Beck disease. Arthritis Rheum 2010; 62: 771-780.
42. Radin ER,. Mechanical aspects of osteoarthritis. Bull Rheum Dis 1976; 23: 862-865.
43. Radin ER, Rose RM,. Role of subchondral bone in the initiating and progression of cartilage damage. Clin Orthop 1986; 213: 34-40.
44. Wood DJ, et al,. Synthesis of alpha-1-antitrypsin by human articular chondrocytes. Trans Orthop Res Soc 1990; 15: 814-815.
45. Koster IM, et al,. Predictive factors for new onset or progression of knee osteoarthritis one year after trauma: MRI follow-up in general practice. Eur Radiol 2011; 21: 1509-1516. [Epub ahead of print].
46. Pelletier JP, et al,. Osteoarthritis, an Inflammatory Disease. Arthritis Rheum 2001; 44: 1237-1247.
47. Kapoor M, et al,. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7: 33-42.
48. Schroeppel JP, et al,. Molecular regulation of articular chondrocyte function and its significance in osteoarthritis. Histol Histopathol 2011; 26: 377-394.
49. Beyer C, Schett G,. Pharmacotherapy: concept of pathogenesis and emerging treatments. Novel targets in bone and cartilage. Best Pract Res Clin Rheumatol 2010; 24: 489-496.
50. Tat SK, et al,. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatol 2009; 48: 1482-1490.
51. Dreier R,. Hypertrophic differentiation of chondrocytes in osteoarthritis: the development aspect of degenerative joint disorders. Arthritis Res Ther 2010; 12: 216.
52. Coleman CM, et al,. Mesenchymal stem cells and osteoarthritis: remedy or accomplice? Hum Gene Ther 2010; 21: 1239-1250.
53. Bertrand J, et al,. Molecular mechanisms of cartilage remodelling in osteoarthritis. Int J Biochem Cell Biol 2010; 42: 1594-1601.
54. Clockaerts S, et al,. The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage 2010; 18: 876-882.
55. Levinger I, et al,. Increased inflammatory cytokine expression in the vastus lateralis of patients with knee osteoarthritis. Arthritis Rheum 2011; 63: 1343-1348.
56. Saito T, Kawaguchi H,. HIF-2α as a possible therapeutic target of osteoarthritis. Osteoarthritis Cartilage 2010; 18: 1552-1556.
57. van den Berg WB,. Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage 2011; 19: 338-341.
58. van der Kraan PM, et al,. Bone morphogenic proteins and articular cartilage to serve and protect or a wolf in sheep's clothing? Osteoarthritis Cartilage 2010; 18: 735-741.
59. Sondergaard B-C, et al,. MAPKS are essential upstream signalling pathways in proteolytic cartilage degradation-divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthritis Cartilage 2010; 18: 279-288.
60. Franke S, et al,. Advanced glycation end products induce cell cycle arrest proinflammatory changes in osteoarthritis fibroblast-like synovial cells. Arthritis Res Ther 2009; 11: R136.
61. Kühn K, et al,. Cell death in cartilage. Osteoarthritis Cartilage 2004; 12: 1-16.
62. Zhang W, et al,. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15: 981-1000.
63. Zhang W, et al,. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
64. Zhang W, et al,. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476-499.
65. Rahme E, et al,. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008; 103: 872-882.
66. Curhan GC, et al,. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164: 1519-1524.
67. Forman JP, et al,. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167: 394-399.
68. Chan AT, et al,. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113: 1578-1587.
69. US Food and Drug Administration. Drug Safety Information. 2009;. Accessed 12 April 2011.
70. Richmond J, et al,. American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. J Bone Joint Surg Am 2010; 92: 990-993.
71. Henrotin Y, Chevalier X,. Guidelines for the management of knee and hip osteoarthritis: for whom? Why? To do what? Presse Med 2010; 39: 1180-1188.